Stockscreener 앱 받기
36.10
0.33%
-0.12
시장 영업 전:
35.01
-1.09
-3.02%
Supernus Pharmaceuticals Inc 주식(SUPN)의 최신 뉴스
Loomis Sayles & Co. L P Reduces Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Segall Bryant & Hamill LLC Invests $791,000 in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
SUPN (Supernus Pharmaceuticals) Operating Margin % : 22.67% (As of Sep. 2024) - GuruFocus.com
Connor Clark & Lunn Investment Management Ltd. Has $6.70 Million Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Pacer Advisors Inc. Buys 403,028 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Supernus Pharmaceuticals (LTS:0LB2) EBITDA per Share : $2.79 (TTM As of Sep. 2024) - GuruFocus.com
Supernus Pharmaceuticals (FRA:S49) Degree of Operating Leve - GuruFocus.com
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q3 2024 Earnings Call Transcript - MSN
Mutual of America Capital Management LLC Sells 75,782 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
56,885 Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Bought by State of New Jersey Common Pension Fund D - MarketBeat
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Purchased by Principal Financial Group Inc. - MarketBeat
Los Angeles Capital Management LLC Takes Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
(SUPN) Technical Data - Stock Traders Daily
ARMISTICE CAPITAL, LLC Adjusts Stake in Supernus Pharmaceuticals Inc - GuruFocus.com
SUPNSupernus Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Supernus Pharmaceuticals Inc (SUPN) Shares Gap Down to $36.57 on Nov 14 - GuruFocus.com
Have Supernus Pharmaceuticals Insiders Been Selling Stock? - Simply Wall St
Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference - The Manila Times
Supernus Pharmaceuticals CEO to Present at Jefferies London Healthcare Conference | SUPN Stock News - StockTitan
GSA Capital Partners LLP Acquires 43,086 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Supernus Pharmaceuticals: Recently Launched Qelbree Is Powering Growth (NASDAQ:SUPN) - Seeking Alpha
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Director Georges Gemayel Sells 14,213 Shares - MarketBeat
Insider Selling: Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) SVP Sells 15,000 Shares of Stock - MarketBeat
Insider Selling: Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) CEO Sells 125,000 Shares of Stock - MarketBeat
Supernus Pharmaceuticals director sells shares worth $520,480 - Investing.com
Supernus Pharmaceuticals SVP Frank Mottola sells $554,700 in stock - Investing.com
Supernus Pharmaceuticals SVP Frank Mottola sells $554,700 in stock By Investing.com - Investing.com UK
Supernus: Q3 Earnings Snapshot - AOL
Supernus Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Earnings call: Supernus Pharmaceuticals reported a significant increase in total revenue - Investing.com Nigeria
Supernus Pharmaceuticals (NASDAQ:SUPN) Reaches New 1-Year High After Strong Earnings - MarketBeat
Supernus Pharmaceuticals Inc (SUPN) Q3 2024 Earnings Call Highli - GuruFocus.com
Supernus Pharmaceuticals Inc (SUPN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates - MSN
Supernus Pharmaceuticals Reports Strong Q3 2024 Results - TipRanks
Supernus Pharmaceuticals Q3 2024 Earnings: EPS of $0.69 Beats Es - GuruFocus.com
Supernus (SUPN) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance
Supernus Announces Third Quarter 2024 Financial Results - GlobeNewswire
Supernus Pharmaceuticals (NASDAQ:SUPN) Posts Quarterly Earnings Results, Beats Estimates By $0.25 EPS - MarketBeat
Supernus Pharmaceuticals (FRA:S49) PE Ratio : 387.50 (As of Nov. 04, 2024) - GuruFocus.com
Q3 2024 Supernus Pharmaceuticals Inc Earnings Call Transcript - GuruFocus.com
Supernus Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Supernus Pharmaceuticals, Inc. Increases Earnings Guidance for the Year 2024 - Marketscreener.com
(SUPN) On The My Stocks Page - Stock Traders Daily
Macquarie Group Ltd Adjusts Stake in Supernus Pharmaceuticals Inc - GuruFocus.com
Stephens Investment Management Group LLC Buys 33,710 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Dimensional Fund Advisors LP Expands Stake in Supernus Pharmaceu - GuruFocus.com
Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024 - The Manila Times
Supernus Presents Promising Data from Open-Label Phase 2a - GlobeNewswire
0.49%
0.82%
자본화:
|
볼륨(24시간):